Bayer Ag S/Adr (OP:BAYRY)

13.31 -1.09 (-7.57%)

Streaming Delayed Price Updated: 3:59 PM EST, Feb 18, 2026 Add to My Watchlist

Price and Volume

Volume	1,135,943
Open	13.32
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	14.40
Today's Range	13.28 - 13.56
52wk Range	5.300 - 14.85
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Bayer's $7.25 Billion Roundup Settlement: A 21-Year Plan for Certainty

Today 10:18 EST

Bayer AG (OTC: BAYRY) has announced a sweeping $7.25 billion proposed class action settlement aimed at resolving the vast majority of its remaining U.S. litigation involving the weedkiller Roundup....

Via MarketMinute

Uncle Sam’s $44.36 Per Acre Gamble: How Government Intervention is Distorting the 2026 Planting Season

Today 10:03 EST

As the 2026 planting season approaches, American farmers are facing a paradox of record-low commodity prices and unprecedented government support. The centerpiece of this intervention is the newly...

Via MarketMinute

Performance

YTD	+20.0%	+20.0%
1 Month	+6.4%	+6.4%
3 Month	+68.3%	+68.3%
6 Month	+63.9%	+63.9%
1 Year	+132.7%	+132.7%

More News

German Pharma Giant Bayer Proposes $7.25 Billion Settlement Over Monsanto's Roundup Cancer Claims In US ↗

Today 6:06 EST

Via Benzinga

Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt ↗

November 23, 2025

Via Stocktwits

Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data

February 16, 2026

Via MarketMinute

Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month

February 12, 2026

From Bayer

Via Business Wire

Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

February 05, 2026

From Bayer

Via Business Wire

Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign

January 29, 2026

From Bayer

Via Business Wire

Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention

January 27, 2026

From Bayer

Via Business Wire

Wall Street’s ‘Fear Gauge’ Reclaims the 20 Mark: Why the Greenland Tariff Threat and Earnings Redlining Triggered a Market Reset

January 20, 2026

Via MarketMinute

Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases

January 20, 2026

From Bayer

Via Business Wire

The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026

January 16, 2026

Via Finterra

Bayer Accelerates Pharma Growth on High-Value Portfolio

January 13, 2026

From Bayer

Via Business Wire

Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause

January 13, 2026

From Bayer

Via Business Wire

Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus

January 12, 2026

From Bayer

Via Business Wire

Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy

January 08, 2026

From Bayer

Via Business Wire

Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference

January 05, 2026

From Bayer

Via Business Wire

Beyond the Bailout: US Farm Groups Demand Structural Reform as USDA Unveils $12 Billion 'Bridge' Program

January 02, 2026

Via MarketMinute

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

December 04, 2025

From Bayer

Via Business Wire

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

December 03, 2025

From Bayer

Via Business Wire

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

December 02, 2025

From Bayer

Via Business Wire

Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations

December 01, 2025

From Bayer

Via Business Wire

Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention

November 23, 2025

From Bayer

Via Business Wire

FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising ↗

November 20, 2025

Via Benzinga

U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

November 20, 2025

From Bayer

Via Business Wire

Frequently Asked Questions

Is Bayer Ag S/Adr publicly traded?

Yes, Bayer Ag S/Adr is publicly traded.

What exchange does Bayer Ag S/Adr trade on?

Bayer Ag S/Adr trades on the OTC Traded

What is the ticker symbol for Bayer Ag S/Adr?

The ticker symbol for Bayer Ag S/Adr is BAYRY on the OTC Traded

What is the current price of Bayer Ag S/Adr?

The current price of Bayer Ag S/Adr is 13.31

When was Bayer Ag S/Adr last traded?

The last trade of Bayer Ag S/Adr was at 02/18/26 03:59 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.